Sensei Biotherapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights

Retrieved on: 2022-05-10 11:32:00

Tags for this article:

Immune system

Medical specialties

Medicine

Clinical medicine

Tumor microenvironment

Immune checkpoint

Monoclonal antibody

Serbian Progressive Party

VISTA

Programmed cell death protein 1

TMAb

sensei biotherapeutics

Sensei Biotherapeutics Inc.

SNS-101

Click the tags to see associated articles and topics

Sensei Biotherapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights. View article details on HISWAI: https://www.globenewswire.com/news-release/2022/05/10/2439604/0/en/Sensei-Biotherapeutics-Reports-First-Quarter-2022-Financial-Results-and-Recent-Business-Highlights.html

Excerpt

Sensei continues preclinical studies to evaluate SNS-101, a monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T ...

Article found on: www.globenewswire.com

View Original Article